Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer
出版年份 2022 全文链接
标题
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer
作者
关键词
-
出版物
JAMA Oncology
Volume -, Issue -, Pages -
出版商
American Medical Association (AMA)
发表日期
2022-10-06
DOI
10.1001/jamaoncol.2022.3755
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
- (2021) Martine Piccart et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- (2021) Alexander M. Menzies et al. NATURE MEDICINE
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Should regulatory authorities approve drugs based on surrogate endpoints?
- (2021) Jeanne Lenzer et al. BMJ-British Medical Journal
- Raising the bar for using surrogate endpoints in drug regulation and health technology assessment
- (2021) Dalia Dawoud et al. BMJ-British Medical Journal
- Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
- (2021) W. Fraser Symmans et al. JAMA Oncology
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
- (2021) H.J. Burstein et al. ANNALS OF ONCOLOGY
- Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
- (2021) Christina Yau et al. LANCET ONCOLOGY
- Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis
- (2021) Fabio Conforti et al. BMJ-British Medical Journal
- Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer
- (2020) E.G. Elia et al. Cancer Epidemiology
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
- (2020) Harold J. Burstein NEW ENGLAND JOURNAL OF MEDICINE
- Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer
- (2020) Carolyn Cullinane et al. JAMA Network Open
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
- (2020) M.J.M. Magbanua et al. ANNALS OF ONCOLOGY
- Residual Disease after Neoadjuvant Therapy — Developing Drugs for High-Risk Early Breast Cancer
- (2019) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto
- (2019) Michael Untch et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
- (2019) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
- (2019) Jeanne Tie et al. JAMA Oncology
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perils of the Pathologic Complete Response
- (2016) Brent S. Rose et al. JOURNAL OF CLINICAL ONCOLOGY
- Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process
- (2015) Sylwia Bujkiewicz et al. STATISTICS IN MEDICINE
- Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)†
- (2014) G. von Minckwitz et al. ANNALS OF ONCOLOGY
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
- (2014) Matthew D Hellmann et al. LANCET ONCOLOGY
- Response-Guided Neoadjuvant Chemotherapy for Breast Cancer
- (2013) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
- (2012) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search